Skip to content
value.today

Aprecia Pharmaceuticals Co

Total raised
$172 M
7 rounds on record
Latest round
$79 M
Jan 2016
First round on record
Dec 2009
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aprecia Pharmaceuticals Co
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2016$79 MNo. 7$50 to $250 million

Aprecia Pharmaceuticals Co: Raise no. 7, Jan 2016

Investors in this round

20 investors had bought by the notice of Jan 28, 2016: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$79 M of $84 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$3,168,907
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Thomas Furniss · Executive Officer
  • Donald Thomas Wetherhold · Executive Officer
  • Michael Thomas Rolhfs · Executive Officer
  • Robert Thomas Williford · Executive Officer
  • E Thomas Arington · Director
  • Etienne Thomas Perold · Director
  • James Thomas Evans · Director
  • Jonathan Thomas Leff · Director
  • Lawrence Thomas Glassmann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS Securities, LLC (CRD 104059) · New York, New YorkSold in CA, MA, MD, NY, OH

Signed by Donald Wetherhold, Ceo. Source: SEC Form D, newest notice filed Jan 28, 2016. Read the notice at the SEC.

equitySEC
Aug 2015$39 MNo. 6$10 to $50 million

Aprecia Pharmaceuticals Co: Raise no. 6, Aug 2015

Investors in this round

8 investors had bought by the notice of Aug 31, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$39 M of $52 M offered; $13 M still to sell
Smallest investment taken
$1
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Thomas Furniss · Executive Officer
  • Donald Thomas Wetherhold · Executive Officer
  • Michael Thomas Rohlfs · Executive Officer
  • Robert Thomas Williford · Executive Officer
  • E Thomas Arington · Director
  • Etienne Thomas Perold · Director
  • James Thomas Evans · Director
  • Lawrence Thomas Glassmann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Donald Wetherhold, Ceo. Source: SEC Form D, newest notice filed Aug 31, 2015. Read the notice at the SEC.

debt, optionsSEC
Nov 2013$15 MNo. 5$10 to $50 million

Aprecia Pharmaceuticals Co: Raise no. 5, Nov 2013

Investors in this round

1 investor had bought by the notice of Dec 10, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $36 M offered; $21 M still to sell
Smallest investment taken
$1
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David A. Furniss · Executive Officer
  • Donald A. Wetherhold · Executive Officer
  • Michael A. Rohlfs · Executive Officer
  • Robert A. Williford · Executive Officer
  • E Thomas Arington · Director
  • Etienne A. Perold · Director
  • Lawrence Thomas Glassmann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Donald Wetherhold, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Dec 10, 2013. Read the notice at the SEC.

debt, optionsSEC
Nov 2012$4 MNo. 4$2 to $10 million

Aprecia Pharmaceuticals Co: Raise no. 4, Nov 2012

Investors in this round

1 investor had bought by the notice of Nov 19, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $9 M offered; $5 M still to sell
Smallest investment taken
$2
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • E Thomas Arington · Executive Officer, Director
  • Glenn S. Vraniak · Executive Officer
  • Lawrence Thomas Glassmann · Executive Officer, Director
  • Michael S. King · Executive Officer
  • Etienne A. Perold · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael King, Cfo. Source: SEC Form D, newest notice filed Nov 19, 2012. Read the notice at the SEC.

debt, optionsSEC
Oct 2011$26 MNo. 3$10 to $50 million

Aprecia Pharmaceuticals Co: Raise no. 3, Oct 2011

Investors in this round

1 investor had bought by the notice of Nov 4, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
$25,725,261
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Don S. Wetherhold · Executive Officer
  • Donald C. Monkhouse · Executive Officer
  • Etienne A. Perold · Executive Officer, Director
  • Glenn S. Vraniak · Executive Officer
  • Michael C. King · Executive Officer
  • E Thomas Arington · Director
  • Lawrence C. Glassmann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael King, Cfo. Source: SEC Form D, newest notice filed Nov 4, 2011. Read the notice at the SEC.

equitySEC
Oct 2010$4 MNo. 2$2 to $10 million

Aprecia Pharmaceuticals Co: Raise no. 2, Oct 2010

Investors in this round

1 investor had bought by the notice of Dec 20, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
$105,000
What was sold
equity
Exemption claimed
  • 06
  • 46
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donald Monkhouse · Executive Officer, Director
  • Etienne Perold · Executive Officer, Director
  • Henry Surprenant · Executive Officer
  • Jaedeok Yoo · Executive Officer
  • Michael King · Executive Officer
  • Joseph Highland · Director
  • Lawrence Glassmann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Donald Monkhouse, President. Source: SEC Form D, newest notice filed Dec 20, 2010. Read the notice at the SEC.

equitySEC
Dec 2009$6 MNo. 1$2 to $10 million

Aprecia Pharmaceuticals Co: Raise no. 1, Dec 2009

Investors in this round

1 investor had bought by the notice of Jan 25, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
$2,500,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donald Monkhouse · Executive Officer, Director
  • Etienne Perold · Executive Officer, Director
  • Henry Surprenant · Executive Officer
  • Jaedeok Yoo · Executive Officer
  • Michael King · Executive Officer
  • Joseph Highland · Director
  • Lawrence Glassmann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Donald Charles Monkhouse, President and CSO. Source: SEC Form D and 1 amendment, newest notice filed Jan 25, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aprecia Pharmaceuticals Co had no revenue when it filed its newest notice of a funding round (Jan 2016).

    SEC Form D (revenue range) · Jan 2016

  • Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2012; revenue of up to $1 million in 2013; no revenue in 2015; no revenue in 2016.

    SEC Form D (revenue range) · Jan 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2016

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Aprecia Pharmaceuticals Co is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aprecia Pharmaceuticals Co
NameRoleNamed in
David Thomas FurnissExecutive officerJan 2016
Donald Thomas WetherholdExecutive officerJan 2016
Michael Thomas RolhfsExecutive officerJan 2016
Robert Thomas WillifordExecutive officerJan 2016
Michael Thomas RohlfsExecutive officerAug 2015
David A. FurnissExecutive officerDec 2013
Donald A. WetherholdExecutive officerDec 2013
Michael A. RohlfsExecutive officerDec 2013
Robert A. WillifordExecutive officerDec 2013
E Thomas AringtonExecutive officerNov 2012
Glenn S. VraniakExecutive officerNov 2012
Lawrence Thomas GlassmannExecutive officerNov 2012
Michael S. KingExecutive officerNov 2012
Don S. WetherholdExecutive officerNov 2011
Donald C. MonkhouseExecutive officerNov 2011
Etienne A. PeroldExecutive officerNov 2011
Michael C. KingExecutive officerNov 2011
Donald MonkhouseExecutive officerDec 2010
Etienne PeroldExecutive officerDec 2010
Henry SurprenantExecutive officerDec 2010
Jaedeok YooExecutive officerDec 2010
Michael KingExecutive officerDec 2010
E Thomas AringtonDirectorJan 2016
Etienne Thomas PeroldDirectorJan 2016
James Thomas EvansDirectorJan 2016
Jonathan Thomas LeffDirectorJan 2016
Lawrence Thomas GlassmannDirectorJan 2016
Etienne A. PeroldDirectorDec 2013
Lawrence C. GlassmannDirectorNov 2011
Donald MonkhouseDirectorDec 2010
Etienne PeroldDirectorDec 2010
Joseph HighlandDirectorDec 2010
Lawrence GlassmannDirectorDec 2010